All In Biotech

Drug Trial Radar · NCT05403710

Targeting Nociceptors in Hidradenitis Suppurativa

Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Jun 7, 2022

Primary completion

Apr 30, 2028

Study completion Apr 30, 2028

Sponsor

Lead sponsor
University of Massachusetts, WorcesterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Hidradenitis Suppurativa Foundation; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); AbbVie
First posted
Jun 3, 2022

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will build on data from mice and humans implicating TRPV1 nociceptors in the pathogenesis of the type-17 chronic inflammatory skin disease Hidradenitis Suppurativa (HS). In this study, the investigators will test the hypothesis that inhibiting neuropeptide activity with botulinum toxin reduces pathogenic inflammation.

Conditions

  • Hidradenitis Suppurativa
  • Hyperhidrosis

Interventions

  • Botulinum toxinDrug

    Administration of botulinum toxin (50 units/100cm2 injected intradermally) into lesional skin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Quantification and phenotyping of skin resident dendritic cell, macrophage, and T cell populations in patients before and after intralesional Botox treatment.Time frame: 1-2 months after first treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Massachusetts Chan Medical School

    Worcester, Massachusetts · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.